Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor- positive breast cancer

Journal of the National Cancer Institute

Volumn 89, Issue 22, 1997, Pages 1673-1682

  Fisher, Bernard ^a,j   Dignam, James ^b   Wolmark, Norman ^c   DeCillis, Arthur ^a   Emir, Birol ^b   Wickerham, D Lawrence ^c   Bryant, John ^b   Dimitrov, Nikolay V ^d   Abramson, Neil ^e   Atkins, James N ^f   Shibata, Henry ^g   Deschenes, Luc ^h   Margolese, Richard G ⁱ  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e Baptist Regional Cancer Institute   (United States)

^f SCCC Community Clinical Oncology Program   (United States)

^g ROYAL VICTORIA HOSPITAL   (Canada)

^h LAVAL UNIVERSITY   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j Allegheny University   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ARTICLE; AXILLARY LYMPH NODE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; ORAL DRUG ADMINISTRATION; PARTIAL MASTECTOMY; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 0030693661     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.22.1673     Document Type: Article

References (17)

1. Consensus conference. Adjuvant chemotherapy for breast cancer. JAMA 1985;254:3461-3.
2. Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320:473-8.
3. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
4. Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996;14:1982-92.
5. Bonadonna G, Valagussa P, Tancini G, Rossi A, Brambilla C, Zambetti M, et al. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1986;1:45-9.
6. Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med 1989;320:485-90.
7. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. The Ludwig Breast Cancer Study Group. N Engl J Med 1989;320:491-6.
8. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
11. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972;34:187-200.
12. Fisher B, Redmond C, Wickerham DL, Wolmark N, Bowman D, Couture J, et al. Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. Ann Intern Med 1989;111:703-12.
13. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. International Breast Cancer Study Group. J Clin Oncol 1997;15:1385-94.
14. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990;8:1005-18.
15. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-81.
16. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-7.
17. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9: 286-94.